natgillin/translations-raw huggingface dataset:
The process according to any of claims 1-13, which further comprises reacting the product obtained in said claims with an appropriate acid to remove the protective group (when R is a protective group) and/or to obtain the desired pharmaceutically acceptable salt. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-13, naznačen time što dodatno uključuje reakciju produkta dobivenog u navedenim patentnim zahtjevima s odgovarajućom kiselinom kako bi se uklonilo zaštitnu skupinu (kada R je zaštitna skupina) i/ili kako bi se dobilo željenu farmaceutski prihvatljivu sol.
The radioimmunoconjugate according to claim 1, wherein the radionuclide is 177Lu. 
Radioimunokonjugat koji se veže za CD37, u skladu sa zahtjevom 1, naznačen time što je radionuklid '"Lu.
A method according to claim 1 wherein said polar aprotic solvent are selected among acetonitrile, dimethylformamide, dimethylacetamide, N-methylpyrrolidone and dimethylsulphoxide. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je navedena polarna aprotonska otopina odabrana iz acetonitrila, dimetilformamida, dimetilacetamida, N-metilpirolidona i dimetilsulfoksida.
The nucleic acid molecule of claim 1, wherein the amino acid residues at the P10-P1 positions have the amino acid sequence of SEQ ID NO:73. 
aminokiseline P10 do P1 se sastoje od sekvence aminokiselina SEK ID BR: 72, SEK ID BR: 73, ili SEK ID BR: 80.
and each elastic ring is configured to seal its respective one of the plurality of inflatable containers upon detachment of the inflatable container from its corresponding hollow tube. The apparatus of claim 1 wherein the housing has a second end (B) at where the plurality of hollow tubes extend from the plurality of holes, and optionally wherein the second end of the housing is located opposite to the first end of the housing. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time, da se svaka rupa od većeg broja rupa (26) na drugom kraju (B) kućišta proteže kroz vanjsku površinu kućišta, pri čemu se vanjska površina na drugom kraju kućišta nalazi na suprotnom kraju kućišta od otvora na prvom kraju (A) kućišta (12).
Use of a tumour associated peptide according to any one of Claims 1 to 6 or a nucleic acid according to Claim 7 or 8 or an expression vector according to Claim 9 for the manufacture of a medicament for inducing an immune response, in particular a cellular immune response, more particularly a T-cell mediated immune response against cells of solid tumours which cells express a human class II MHC molecule on their surface and present a polypeptide comprising an amino acid sequence as given in any of Claims 1 to 4. 
Upotreba tumoru pridruženih peptida prema Zahtjevu 1. ili 2. ili nukleinske kiseline prema Zahtjevu 4., ili vektora ekspresije prema Zahtjevu 5. za proizvodnju lijekova za indukciju imunološkog odgovora, posebice staničnog imunološkog odgovora, specifičnije za imunološki odgovor posredovan T limfocitima protiv stanica solidnih tumora koje eksprimiraju humane MHC molekule razreda II na svojoj površini te prikazuju polipeptid koji se sastoji od slijeda aminokiselina navedenog u Zahtjevu 1. ili 2.
x are the atoms of the element BVI, and 2-x are the atoms of the element AVI. Solar concentrator according to Claim 1, characterized in that the nanocrystals contain metals such as copper, silver, zinc, aluminium, indium and gallium. 
X su atomi elementa B", i 2-x su atomi elementa A*', Koncentrator sunčevog zračenja u skladu s patentnim zahtjevom 1, naznačen time što nanokristali sadrže metale poput bakra, srebra, cinka, aluminija, indija i galija.
The composition according to any one of claims 1-3, wherein the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable excipient, carrier or diluent. 
Farmaceutski pripravak naznačen time da sadrži Bacteroides thetaiotaomicron koji je definiran u zahtjevu 1, te farmaceutski prihvatljivo pomoćno sredstvo, nosač ili otapalo.
A nucleic acid molecule which encodes an antigen binding protein as defined in any one of claims 1-10, optionally wherein the nucleic acid sequence comprises SEQ ID NO:54 and/or SEQ ID NO:59, optionally wherein the nucleic acid sequence comprises SEQ ID NO:61 and/or SEQ ID NO:63. An expression vector comprising a nucleic acid molecule as defined in claim 11. 
Molekula nukleinske kiseline u skladu s patentnim zahtjevom 3, naznačena time što sadrži SEQ ID NO:54 i SEQ ID NO:59. Molekula nukleinske kiseline u skladu s patentnim zahtjevom 3, naznačena time što sadrži SEQ ID NO:61 i SEQ ID NO:63. Ekspresijski vektor, naznačen time što sadrži molekulu nukleinske kiseline u skladu s patentnim zahtjevom 3, 4 ili 5.
Compound according to one of Claims 1 to 7, characterized in that it is 2-(2-methyl-5-nitroimidazol-1-yl)ethyl (S)-2-(2-fluorobiphenyl-4-yl)propionate. 
Spoj prema jednom od zahtjeva 1 do 7, naznačen time što je to 2(2-metil-5-nitroimidazol-1-iljetil (S)-2-(2- fluorobifenil-4-il)propionat.
An isolated polypeptide, the isolated polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:2. 
Izolirani polipeptid, naznačen time što izolirani polipeptid sadrži anti-STAT3 antitijelo s jednom domenom (sdAb) koje sadrži aminokiselinsku sekvencu kao što je navedena u SEQ ID NO:3.
In another aspect Ring A is a cyclopropyl ring. 
HR P20140953 T1 Prsten A je ciklopropil prsten;
substituted and unsubstituted cycloalkyl; 
supstituirani i nesupstituirani cikloalkil;
The method of claim 4, wherein the matrix is selected from: laminin, fibronectin, vitronectin, proteoglycan, entactin, collagen, collagen I, collagen IV, collagen VIII, heparan sulfate, a soluble preparation from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, a human basement membrane extract, and any combination thereof. 
Postupak prema zahtjevu 1 koji nadalje sadrži kulturiranje CEC na matrici odabranoj od laminina, fibronektina, vitronektina, proteoglikana, entaktina, kolagena, kolagena I, kolagena IV, kolagena VIII, heparan sulfata, topljivog pripravka iz Engelbreth-Holm-Swarm (EHS) stanica mišjeg sarkoma, ekstrakta osnovne ljudske membrane, i bilo koje njihove kombinacije.
Compound (II) as an oxalate salt in methanol is added to a suspension of 10% pre-hydrogenated palladium on charcoal in methanol, and the mixture is then stirred under hydrogen at 3.44 x 105Pa (50 p.s.i.) 
Spoj (11) kao oksalatna sol u metanol u dodaje se na suspenziju 10% pre-hidrogeniziranog paladija na ugljenu u metanolu, i smjesa se tada miješa pod vodikom na 50 D.S.i.
A method of coating a substrate according to claim 1, wherein the topcoat system is a fouling release system, preferably consisting of, an optional underlying primer coat; 
Metoda premazivanja supstrata sukladno zahtjevu 1, naznačena time, što je sustav završnog premaza neobraštajući premaz, a koji se po mogućnosti sastoji od
Vinification tank according to any one of the preceding claims, wherein said nozzles (2) are mounted equispaced, optionally mounted at the same height and equispaced angularly to each other. 
Viifikacijski spremnik 1 uređaj prema bilo kojem od patentnih zahtjeva 1 do 4, gdje su spomenute mlaznice (2) montirane u jednakim udaljenostima jedna od druge.
A beehive with separating additionally redirecting partitions (6), as per claim 1, characterized in that they can be perforated with selective holes to let in only the worker bees and not the queen bee. 
Pčelinja košnica s preusmjeravajućim pregradama za dodatnu podjelu (6) sukladno zahtjevu 1., koje su karakteristične po tomu što se mogu perforirati selektivnim otvorima koji propuštaju pčele radilice, ali ne 1 maticu.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
A combination of a proteasome inhibitor, wherein said proteasome inhibitor is bortezomib, and a histone deacetylase inhibitor wherein said histone deacetylase inhibitor is compound No. 1a (JNJ26481585) the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof. 
1. 10 Kombinacija, naznačena time, da sadrži inhibitor proteasoma, pri čemu je navedeni inhibitor proteasoma bortezomib, te inhibitor histonske deacetilaze, pri čemu je navedeni inhibitor histonske deacetilaze spoj br. la
Process for the reduction to amine of a nitro group present in an aliphatic, cycloaliphatic, aromatic or heteroaromatic compound, wherein said compound is reacted with trichlorosilane in the presence of a base. 
Postupak za redukciju nitro skupine koja je prisutna u alifatskom, cikloalifatskom, aromatskom ili heteroaromatskom spoju u amin, naznačen time, da rečeni spoj ragira s triklorosilanom u nazočnosti lužine.
The molecule was also without effect in relieving acute ischemic pain in humans. 
Ova molekula također nije imala učinka u popuštanju akutne ishemijske boli u ljudima.
The method of claim 4 wherein the drive signal having the first frequency or the drive signal having the second frequency have a variable pulse duration and/or timing. 
Sustav prema zahtjevu 1, naznačen time, da je sustav namješten tako da primarni pokretački signal ili sekundarni pokretački signal ima promjenjivo vrijeme trajanja impulsa i/ili izbor trenutka - tajming.
The method of claim 1, wherein the metal carbonyl compound has a formula [QMy(CO)w]x, wherein: Q is any ligand or more than one ligand and need not be present; M is a metal atom; 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je prevođenje etilen-oksida u fB-propiolakton reakcija u plinovitoj fazi, ili: gdje metalni karbonilni spoj ima formulu [QM,(CO),]", gdje:
is an optionally substituted aliphatic, aromatic, or heteroaromatic group; 
R! je izborno supstituirana alifatična, aromatična ili heteroaromatična grupa;
It is consequently desirable to provide formulations and methods for making the same that provide embodiments whose composition does not readily and unpredictably change by the uncontrolled formation of impurities. 
Kao posljedica toga, poželjno je osigurati oblike i postupke za pripremu istih koji osiguravaju varijante čiji se sastav ne mijenja lako i neočekivano preko nekontroliranog stvaranja nečistoća.
an agent for increasing HDL or limiting HDL decrease, optionally a statin, bile acid sequestrant (BAS), cholesterol absorption inhibitor, fibrate or other PPAR alpha agonist, dual PPAR agonist, lipase inhibitor, protein tyrosine phosphatase 1B inhibitor, pancreatic peptide YY3-36, recombinant or other cannabinoid receptor antagonist, or 5-HT2c agonists, such as lorcaserin; 
(b) agens za podizanje HDL-a ili ograničavanje snižavanja HDL-a, opcionalno statin, sekvestrant žučnih kiselina (BAS), inhibitor apsorpcije kolesterola, fibrat ili drugi agonist PPAR alfa, dvostruki PPAR agonist, inhibitor lipaze, inhibitor protein tirozin fosfataze 1B, pankreasni peptid YY334, rekombinantni ili drugi antagonist kanabinoidnog receptora ili 5-HT2c agonist, kao što je lorkaserin;
ii) obtaining the compound of formula (I), according to any one of the processes defined in claims 9 to 12, preferably according to the process defined in claim 11. 
proizvodnja spoja formule (II) prema zahtjevu 4, prema bilo kojem postupku definiranom u zahtjevima 4 do 8, poželjno prema postupku definiranom u zahtjevu 7; i dobivanje spoja formule (I), prema bilo kojem postupku definiranom u zahtjevima 9 do 12, poželjno prema postupku definiranom u zahtjevu 11.
The method of claim 17, wherein the endogenous mouse Vλ gene segments of the second endogenous Vλ-Jλ-Cλ gene cluster have been replaced with a contiguous sequence of the human immunoglobulin light chain locus that spans from a human Vλ3-27 gene segment to a human Vλ3-1 gene segment and a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ5-52 gene segment to a human Vλ1-40 gene segment. 
Miš prema patentnom zahtjevu 1, naznačen time, što miš sadrži: od 12 do 40 nepreuređenih segmenata gena varijabilne regije humanog imunoglobulinskog lakog lanca A (hV2) i najmanje jedan humani segment gena JA (hJA); 1 humanu međugensku sekvencu nukleinske kiseline VK-JK smještenu između 12 do 40 segmenata gena varijabilne regije humanog imunoglobulinskog lakog lanca i najmanje jedne sekvence nukleinske kiseline JA.
or an amide, an ester or a salt of the polypeptide. 
PY; ili amid, ester ili sol polipetida.
The binding reaction is pH dependent and elution is carried out by reducing the pH and increasing the ionic strength of the buffer or by including EDTA in the buffer. 
Vezna reakcija je ovisna o pH, a ispiranje se provodi smanjivanjem pH te povećanjem ionske jakosti pufera ili dodavanjem EDTA u pufer.
In some embodiments, compounds of the present invention are of Formula (Iu) wherein X is O (an oxygen atom). 
U nekim oblicima, spojevi prema izumu su Formule (Iu) gdje X je O (atom kisika).
Lyophilisation will typically take place within vials, with sealing after lyophilisation. 
Liofilizacija će se tipično izvoditi unutar bočica, s brtvljenjem nakon liofilizacije.
Alternatively, the matrix material or release retarding coating can take the form of an erodible polymer (e.g. a maleic anhydride polymer) which is substantially continuously eroded as the dosage form passes through the gastrointestinal tract. 
Altenativno, materijal matriksa ili prevlaka za usporavanje oslobađanja mogu biti u obliku erozivnog polimera (na primjer polimera maleinskog anhidrida) koji prolaskom dozirnog oblika kroz probavni trakt gotovo stalno erodira.
an amino group which may be a saturated cyclic amino group which may be substituted by a group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl; 
aminske skupine koja može biti zasićena ciklaminska skupina, koja može biti supstituirana skupinom koja se sastoji od alkila, alkoksikarbonila, halogena, haloalkila, hidroaksialkila, amina, monoalkilamina, dialkilamina, karbamoila, monoalkilkarbamoila i dialkilkarbamoila
After mixing at 3-4 hours at room temperature, reactions were filtered through Packard Unifilter GF/C plates using a Packard Harvester, and washed with 8 X 200 µl ice-cold binding buffer. 
Nakon miješanja tijekom 3-4 sata na sobnoj temperaturi, reakcije su filtrirane kroz Packard Unifilter GF/C ploče korištenjem Packard Harvester-a, te je provedeno ispiranje s 8 X 200 pl ledeno-hladnog pufera za vezivanje.
No. 4,235,877. A further aspect of the invention is a vaccine kit for concomitant or sequential administration comprising two multi-valent immunogenic compositions for conferring protection in a host against disease caused by Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae and Neisseria meningitidis and optionally Haemophilus influenzae . 
Cjepivni komplet za istodobnu ili uzastopnu primjenu, naznačen time što sadrži dva polivalentna imunogena pripravka za postizanje zaštite kod domačina protiv bolesti koje uzrokuju bakterije Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, te Haemophilus influenzae, gdje navedeni komplet sadrži prvi spremnik, koji sadrži: tetanusni toksoid (TT), t>&
imiquimod, having the specific formula 1-isobutyl-1 H -imidazo[4,5- c]quinolin-4-amine, selected from following formula (X): and 
€) imikimod, koji ima specifičnu formulu 1-izobutil-1H-imidazo[4,5-c]kinolin-4-amin, koji je odabran iz slijedeće formule (X):
The process of claim 1, wherein, the organic solvent used in said step 1) is petroleum ether, methanol, ethanol, propanol or ethyl acetate. The process of claim 1, wherein, the liposoluble component in the step 1) is volatile oils, flavonoids, triterpenoids or saponins. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je organsko otapalo upotrijebljeno u navedenom koraku 1) petroleter, metanol, etanol, propanol ili etil-acetat; i/ili gdje je liposolubilna komponenta u koraku 1) hlapljiva ulja, flavonoidi, triterpenoidi ili saponini; i/ili gdje je alkohol upotrijebljen u navedenom koraku 3) etanol.
Pharmaceutical composition according to claim 14 comprising PRLR antibodies or antigen-binding fragments or maturated variants thereof to any of claims 1 to 4 for use by parenteral administration, whereby methods of parenteral delivery include topical, intra-arterial, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, intrauterine, vaginal, or intranasal administration. 
Farmaceutski pripravak prema zahtjevu 14 koji sadrži PRLR antitijela ili fragment koji veže antigene ili njihove sazrele varijante prema bilo kojem od zahtjeva 1 do 4, naznačen time da je za uporabu putem parenteralno davanje, pri čemu postupci parenteralne primjene uključuju lokalnu, intraarterijsku, intramuskularnu, potkožnu, intramedulamu, intratekalnu, intraventrikularnu, intravenoznu, intraperitonealnu, intrauterinu, vaginalnu, ili intranazalnu primjenu.
A method for treating a cancer patient sensitive to treatment with a WEE1 inhibitor comprising: 
Inhibitor WEE1 za upotrebu u liječenju pacijenta oboljelog od karcinoma osjetljivog na liječenje inhibitorom WEEI1 koja sadrži:
The compound of claim 1, where X is —CH(R15)—OR16 and has formula e: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je X je -CH(R'*)-OR'* i ima formulu e:
Mineral oil has no effect on flexibility, although it can act to maintain some of the flexibility imbued by water. 
Mineralno ulje nema utjecaj na fleksibilnost, iako može djelovati tako da zadrži nešto fleksibilnosti kad je nokat namočen vodom.
In a first aspect, the invention provides a compound of formula VI: 
Spoj, naznačen time, da ima formulu VI:
In addition, the surface of microcarriers may be coated with a material promoting cell attachment and growth such as, e.g., e.g., N,N-diethylaminoethyl, glass, collagen or recombinant proteins. 
Dodatno, površina mikronosača može biti omotana s materijalom koji pospješuje priljepljivanje stanica i rast poput, na primjer N,N-dietilaminoctila, stakla, kolagena ili rekombinantnih proteina.
To a stirred -5°C solution of gluconolactone (239g, 1.34 mol) and N-methylmorpholine (1180 mL, 10.73 mol) in 2.4L of THF under Ar was added trimethylsilyl chloride (1022 mL, 8.05 mol) via dropping funnel at a rate such that the temperature did not exceed 5°C. 
U mješanu -5"C otopinu glukonolaktona (239 g, 1.34 mol) i N-metilmorfolina (1180 mL, 10.73 mol) u 2.4 1 THF pod Ar dodavan je trimetilsilil klorid (1022 ml, 8.05 mol) preko lijevka za ukapavanje takvom stopom da temperatura nije prešla 5C.
performing, by the processor, intra prediction on the current block using the intra prediction mode of the current block. The method of claim 1, wherein the candidate intra prediction modes include the intra prediction mode of the left block, when the intra prediction mode of the left block is equal to the intra prediction mode o the upper block and the intra prediction mode of the left block is not equal to the DC mode. 
- < provođenje unutrašnjeg predviđanja trenutnog bloka uz korištenje načina predviđanja, koji je određen s indeksom načina, između kandidata načina unutrašnjeg predviđanja koji su uključeni u popis kandidata, naznačen time da popis kandidata načina unutrašnjeg predviđanja sadrži ravninski način, kada su načini unutrašnjeg predviđanja lijevog bloka 1 gornjega bloka međusobno jednaki i unutrašnji način lijevog bloka je DC način.
In a further embodiment of the invention directed to the process of making the liquid long acting injectable formulation of the invention, the liquid long acting injectable formulation is free of particles which plug the needle used for injection wherein the needle gauge is selection from the group consisting of about 18 to about 30, about 18 to about 24 and about 24 to about 30. 
Postupak prema zahtjevu 6, naznačen time, da je tekuća injektibilna formulacija s produljenim djelovanjem oslobođena od čestica koje začepljuju iglu koja se koristi za injekciju, pri čemu je kalibar igle odabran iz skupine koju čine: oko 16 do oko 30, oko 18 do oko 24 i oko 24 do oko 30.
According to a preferred embodiment the peptide is coupled to a pharmaceutically acceptable carrier, preferably KLH (Keyhole Limpet Hemocyanin). 
Peptid prema zahtjevu 15, naznačen time, da je taj peptid spojen na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
wherein at least 90% of all said micronized particles of said active ingredients (c) have a volume diameter equal to or lower than 5.0 microns, and the volume median diameter of said particles is from 1.3 to 2.2 microns. 
Formulacija suhog praška prema patentnom zahtjevu 1 ili 2, naznačeno time da najmanje 90% mikroniziranih čestica aktivnih tvari ima volumni promjer jednak ili manji od 5,0 mikrona.
The clip assembly according to claim 5, wherein each U-shaped clip of the sets of juxtaposed clip assemblies of which the front portions are aligned in the transverse direction include holes for securing at least one stem, wherein the holes of at least one in two juxtaposed clip assemblies of the set of juxtaposed clip assemblies are offset in a longitudinal direction in relation to holes of at least one of the contiguous clip assemblies. 
Štipaljke prema zahtjevima 5 ili 6, naznačene time, što su u sklopovima usporednih štipaljki čiji su prednji dijelovi poredani u poprečnom pravcu, rupe za prolaz (7) sredstava za fiksiranje pomoću šipke svake druge usporedne štipaljke, pomaknute u uzdužnom pravcu u odnosu na rupe za prolaz sredstava za fiksiranje pomoću šipke susjedne štipaljke ili susjednih štipaljki.
More specifically the Mtb72f is: a polypeptide comprising residues 8-729 of SEQ ID NO:2; or a polypeptide consisting of residues 1 and 8-729 of SEQ ID NO:2 optionally with a His tag inserted following the initial Met residue; or 
Farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što je fuzijski protein Mtb72f polpeptid koji se sastoji od ostataka 1 i 8-729 iz SEQ ID NO:2, izborno s ubačenim biljegom His iza početnog ostatka Met.
The method according to claim 8, wherein the metal surface is steel. 
čelična, koja je prema potrebi prethodno obrađena tako da bude otporna prema koroziji i da je adhezivna prema sastavu premaza.
The method of claim 1, wherein the biological target is a nucleic acid and the encoded probes are oligonucleotides. 
Metoda prema patentnom zahtjevu 3, gdje su biološke mete nukleinske kiseline i kodirane probe su oligonukleotidne probe.
The pharmaceutical composition according to claim 46 further comprising at least one of an anticancer agent, a chemotherapy agent, or an antiproliferative compound. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 47, naznačen time što dodatno sadrži najmanje jedno sredstvo, koje se bira između sredstva protiv raka, kemoterapeutskog sredstva, te antiproliferativnog spoja.
is H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxyalkyl, C2-C6 alkylcarbonyl, or benzyl, wherein the benzyl may be optionally substituted with 1-3 R4; alternatively R8 and R9 may be taken together to form a 5- or 6- membered saturated or unsaturated ring containing 1-3 heteroatoms wherein each ring may be optionally substituted with 1-3 R4. A composition for the control of a fungal pathogen including the compound of Claim 1 and a phytologically acceptable carrier material. 
R? je H, Ci-Cs alkil, C;-Cg haloalkil, C;-Cg alkoksialkil, C»-C4 alkilkarbonil, ili benzil, u čemu benzil može po izboru biti supstituiran s 1-3 R*; alternativno RÅ i R? mogu se uzeti zajedno da oblikuju 5- ili 6-člani zasićeni ili nezasićeni prsten koji sadrži 1-3 heteroatoma, u čemu svaki prsten može po izboru biti supstituiran s 1-3 R*. HR P20171776 T1 Sastav za suzbijanje gljivičnog patogena, naznačen time, da uključuje spoj iz patentnog zahtjeva 1 i fitološki prihvatljivu tvar nosioca.
is alkyl, alkenyl, alkynyl, or halogen, wherein said alkyl is unsubstituted or substituted with one or more Rc; 
R* je alkil, alkenil, alkinil ili halogen, pri čemu je navedeni alkil nesupstituiran ili supstituiran s jednim ili više R;